儿童癌症中的可变剪接缺陷:肿瘤发生的新见解与潜在治疗脆弱性
本文综述可变剪接在儿童癌症中的作用,包括癌症易感综合征和多种儿童肿瘤;并在本机构罕见、难治及复发儿童与青少年年轻成人癌症队列中通过综合基因组分析确认多个剪接变异,总结其对新抗原和化疗耐药的影响及剪接靶向治疗前景。
要点
- 已报道的剪接失调事件可分为外显子纳入、外显子排除、剪接因子上调或剪接位点改变。
- 本机构队列在CHEK2、TP53、PIK3R1、MDM2、KDM6A、NF1等关键调控基因中显示剪接变异,预测影响功能蛋白表达并促进肿瘤发生。
- 剪接改变策略包括反义寡核苷酸、腺相关病毒基因转移和小分子抑制剂,可能改变儿童癌症治疗格局。
核心结论
- 可变剪接在儿童癌症的形成和生长中起关键作用,本机构队列确认并强调了多种癌症中受影响基因的广泛谱系。
- 进一步研究阐明疾病诱导剪接事件的机制将有助于新型治疗方法的开发。
研究设计与样本
- 综述现有关于可变剪接在成人癌症、癌症易感综合征和儿童癌症中作用的文献。
- 描述在成人癌症中识别并通过综合基因组分析在本机构罕见、难治和复发儿童及青少年年轻成人癌症患者队列中确认的多个剪接变异。
- 总结可变剪接事件对新抗原和化疗耐药的贡献以及基于剪接的治疗前景。
主要发现
- 已发表的剪接失调事件可分为外显子纳入、外显子排除、剪接因子上调或剪接位点改变。
- 在癌症易感综合征(Lynch综合征、Li-Fraumeni综合征、CHEK2)和儿童白血病(B细胞急性淋巴细胞白血病)、肉瘤(Ewing肉瘤、横纹肌肉瘤、骨肉瘤)、视网膜母细胞瘤、Wilms瘤和神经母细胞瘤中观察到这些现象。
- 在本机构队列中,关键调控基因(CHEK2、TP53、PIK3R1、MDM2、KDM6A、NF1)的剪接变异导致外显子排除或剪接位点改变,预测影响功能蛋白表达并促进肿瘤发生。
- 差异剪接的异构体和剪接蛋白也影响新抗原产生和治疗耐药,如伊马替尼或糖皮质激素方案。
关键数值与推荐
- 已报道的剪接失调事件分类:外显子纳入、外显子排除、剪接因子上调或剪接位点改变。
- 本机构队列中关键调控基因剪接变异导致外显子排除或剪接位点改变,预测影响功能蛋白表达并促进肿瘤发生。
- 剪接改变策略包括反义寡核苷酸、腺相关病毒基因转移和小分子抑制剂。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Compared with adult cancers, pediatric cancers are uniquely characterized by a genomically stable landscape and lower tumor mutational burden. Alternative splicing, however, a global cellular process that produces different messenger RNA/protein isoforms from a single messenger RNA transcript, has been increasingly implicated in the development of pediatric cancers. DESIGN: We review the current literature on the role of alternative splicing in adult cancer, cancer predisposition syndromes, and pediatric cancers. We also describe multiple splice variants identified in adult cancers and confirmed through comprehensive genomic profiling in our institutional cohort of rare, refractory, and relapsed pediatric and adolescent young adult cancer patients. Finally, we summarize the contributions of alternative splicing events to neoantigens and chemoresistance and prospects for splicing-based therapies. RESULTS: Published dysregulated splicing events can be categorized as exon inclusion, exon exclusion, splicing factor up-regulation, or splice site alterations. We observe these phenomena in cancer predisposition syndromes (Lynch syndrome, Li-Fraumeni syndrome, CHEK2) and pediatric leukemia (B-cell acute lymphoblastic leukemia), sarcomas (Ewing sarcoma, rhabdomyosarcoma, osteosarcoma), retinoblastoma, Wilms' tumor, and neuroblastoma. Within our institutional cohort, we demonstrate splice variants in key regulatory genes (CHEK2, TP53, PIK3R1, MDM2, KDM6A, NF1) that resulted in exon exclusion or splice site alterations, which were predicted to impact functional protein expression and promote tumorigenesis. Differentially spliced isoforms and splicing proteins also impact neoantigen creation and treatment resistance, such as imatinib or glucocorticoid regimens. Additionally, splice-altering strategies with the potential to change the therapeutic landscape of pediatric cancers include antisense oligonucleotides, adeno-associated virus gene transfers, and small molecule inhibitors. CONCLUSIONS: Alternative splicing plays a critical role in the formation and growth of pediatric cancers, and our institutional cohort confirms and highlights the broad spectrum of affected genes in a variety of cancers. Further studies that elucidate the mechanisms of disease-inducing splicing events will contribute toward the development of novel therapeutics.
引用
- Venkataramany AS, Schieffer KM, Lee K, et al. Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities. Ann Oncol. 2022. PMID: 35339647. doi:10.1016/j.annonc.2022.03.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。